EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Thorsten Oliver Götze, Sven Perner, Kim Luley, Christian Moritz Heyer, Carolina de la Torre, Ralf-Dieter Hofheinz, Sylvie Lorenzen und 1 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.01.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Isabel Porth und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany. Electronic address: isabel.porth@medma…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft, Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophageal NeoplasmsHumansTrastuzumabB7-H1 AntigenRetrospective StudiesErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorEsophagogastric JunctionAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Gastric cancerHER2PD-L1Prognostic factorTrastuzumab

Substanzen

TrastuzumabB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany. Electronic address: isabel.porth@medma.uni-heidelberg.de.
  • Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
  • Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Institute of Pathology, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, 81675 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich; Bavarian Cancer Center (BZKF), Germany.
  • Institute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany; IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, 60488 Frankfurt, Germany.
  • Institute of Pathology, University of Luebeck and University Hospital Schleswig-Holstein Campus Luebeck, 23538 Luebeck, Germany; Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.

Förderung

  • Deutsche Krebshilfe
  • Deutsche Forschungsgemeinschaft
  • Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg

Zitieren

APA

Porth, I., Hirsch, D., Ceribas, Y., Weidner, P., Weichert, W., Götze, T. O., Perner, S., Luley, K., Heyer, C. M., de la Torre, C., Hofheinz, R. D., Lorenzen, S., & Gaiser, T. (2023). Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.022

Vancouver

Porth I, Hirsch D, Ceribas Y, Weidner P, Weichert W, Götze TO, et al. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.022

BibTeX
@article{Porth2023,
  author = {Porth, Isabel and Hirsch, Daniela and Ceribas, Yonca and Weidner, Philip and Weichert, Wilko and Götze, Thorsten Oliver and Perner, Sven and Luley, Kim and Heyer, Christian Moritz and de la Torre, Carolina and Hofheinz, Ralf-Dieter and Lorenzen, Sylvie and Gaiser, Timo},
  title = {Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.01.022}
}
Kostenlos starten →